ArticleFrontiers in oncology2026
Myoepithelioma-like tumor of the vulvar region with estrogen receptor negativity and
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myoepithelioma-like tumor of the vulvar region (MELTVR) is a rare mesenchymal neoplasm that exhibits morphological features resembling those of soft tissue myoepitheliomas, yet displays distinct immunophenotypic and molecular genetic characteristics. All MELTVR cases reported in the existing literature have been estrogen receptor (ER)-positive. In contrast, this study presents the first documented case of ER-negative MELTVR, thereby broadening the known immunohistochemical phenotypic spectrum of this neoplasm. Next-generation sequencing (NGS) analysis revealed copy number loss of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.